Merck: discontinues two candidate Covid vaccines

(CercleFinance.com) - Merck (MSD outside the US and Canada), has announced that it is halting development of its Covid-19 vaccine candidates V590 and V591, following the review of disappointing Phase I clinical trial results in terms of immune responses to these vaccines.


As a result, the pharmaceutical group will record a charge in its GAAP accounts for Q4 2020, although this will not impact its adjusted results.

The US pharmaceutical group plans to focus its research strategy and production capacities on developing two therapeutic candidates, MK-7110 and MK-4482 (molnupiravir), with the latter being developed in collaboration with Ridgeback Bio.


Copyright (c) 2021 CercleFinance.com. All rights reserved.